MBX Biosciences (MBX) Enterprise Value (2023 - 2026)
MBX Biosciences (MBX) posted Enterprise Value of -$440.0 million for Q1 2026, down 17.73% sequentially from -$373.7 million in Q4 2025, and down 82.73% YoY from -$2.5 billion in Q1 2025.
MBX Biosciences (MBX) Enterprise Value (2023 - 2026) Analysis & Trends
MBX Biosciences has reported Enterprise Value for 4 years, with the latest figure at -$440.0 million in Q1 2026.
- Quarterly Enterprise Value fell 82.73% year-over-year to -$440.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$440.0 million (down 82.73% YoY) and the FY2025 annual result came in at -$373.7 million, down 42.55% from the prior year.
- Enterprise Value slipped to -$440.0 million in Q1 2026 per MBX's latest filing, from -$373.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at $115.9 million in Q2 2024 and troughed at -$440.0 million in Q1 2026.
- A 4-year average of -$187.8 million and a median of -$240.8 million in 2025 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 859.06% in 2024, then plunged 41.37% in 2025.
- Over 4 years, Enterprise Value stood at -$44.2 million in 2023, then slumped by 493.43% to -$262.1 million in 2024, then tumbled by 42.55% to -$373.7 million in 2025, then retreated by 17.73% to -$440.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$440.0 million, -$373.7 million, and -$391.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | MBX Biosciences | 3.29 Bn | 3.29 Bn | - | -418.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -418.58 Mn |
| Mar 31, 2026 | -439.98 Mn |
| Dec 31, 2025 | -373.71 Mn |
| Sep 30, 2025 | -391.67 Mn |
| Jun 30, 2025 | -224.91 Mn |
| Mar 31, 2025 | -240.79 Mn |
| Dec 31, 2024 | -262.15 Mn |
| Sep 30, 2024 | -277.06 Mn |
| Jun 30, 2024 | 115.86 Mn |
| Mar 31, 2024 | 36.50 Mn |
| Dec 31, 2023 | -44.18 Mn |
| Sep 30, 2023 | 36.50 Mn |